On March 18-22, 2025, Compass Bioinformatics US team headed to Los Angeles for the 2025 ACMG Annual Clinical Genetics Meeting! We were excited to connect with the global genetics community and demonstrated how InheriNext®, our domain-specific, AI-powered genetic analysis platform, is transforming rare disease diagnostics and accelerating precision medicine.
About ACMG
The American College of Medical Genetics and Genomics (ACMG) empowers members to be leaders in integrating genetics and genomics into medicine and healthcare. Its mission spans:
Advancing clinical research and promoting the use of genomic medicine
Advocating for professionals and patients, including reimbursement for clinical and laboratory genomic services and protection of personal genetic information
Providing practice resources, guidelines, and standards for medical genetics to improve patient care and inform the responsible application of genomics in medicine
The ACMG Annual Clinical Genetics Meeting provides the perfect platform for Compass Bioinformatics to showcase how AI-driven genetic analysis can support clinicians, accelerate variant interpretation, and improve outcomes in rare disease management.
On this note, InheriNext® automatically classifies variant sites according to the 28 ACMG guideline criteria—the industry standard—helping clinicians streamline interpretation and reduce the time and complexity of comprehensive assessments. Users can also manually adjust settings based on their clinical experience and scientific knowledge to generate a thorough, customized result.
New connections visited Booth #333 in the Startup Pavilion to explore how the InheriNext® platform combines advanced bioinformatics tools and genomic data analysis to deliver actionable insights for clinicians and researchers.
Alongside networking and discussions with peers, we were thrilled to reconnect with friends from Genomenon, Inc. and Revvity, strengthening our collaborations in the genomics and rare disease space.